Date, Stephanie2022-11-012022-11-012022-01-28https://hdl.handle.net/2139/54435Epidemiological data were collected from Barbadian women diagnosed with Endometrial cancer (EC), with and without exposure to the anti-diabetic agent, Metformin. All recorded primary cases of EC diagnosed between January 1st, 2008, and December 31st, 2017, were analysed. Age-specific incidence, and crude mortality rates were calculated. Descriptive statistics characterized demographics, risk factors, prescription data and histopathology. Log-rank tests assessed simple group differences by EC type. Survival analysis based on tumour type was plotted using Kaplein-Meir curves. Serum and EC tissue samples from eligible women diagnosed with EC in 2020 were collected for future hormonal and biomarker analysis. There were 270 recoded cases of EC, averaging 66 (8.8) years old, with parity of 3.60 (2.3). Cases were postmenopausal with 95% experiencing postmenopausal bleeding. There were 42% were type 1, 58% type 2 tumours. Weak evidence suggests the latter imparted worse survival (log rank test = 0.02). There was no statistically important difference in survival between women with and without a history of metformin use. Estimated crude incidence rate was 18.64 per 100,000 women. Crude mortality rate from EC between January 1st, 2008 and December 31st, 2019 was 27%. ELISA testing was performed on all serum samples collected and analysis is ongoing. Tissue microarrays were created and will be stained and scanned for biomarker analysis.enOther